A U.S. Senate panel grilled secretive pharmacy benefit managers in a hearing Thursday on how to bring fairness and transparency to U.S. drug pricing.
Although the bipartisan criticism was part of a growing chorus at the federal level against PBMs, the big question is: Will anything be done about it?
The question is important because the drug benefits of more than 265 million Americans are handled by PBMs, middlemen in the murky drug supply web whose other major players include pharmaceutical companies, health insurers and pharmacies.